Catheter lock heparin concentration: Effects on tissue plasminogen activator use in tunneled cuffed catheters

Hemodialysis International

Volumn 11, Issue 1, 2007, Pages 96-98

  Holley, Jean L ^a   Bailey, Sandra ^a  

^a UNIVERSITY OF VIRGINIA HEALTH SYSTEM   (United States)

Author keywords

Catheter clotting; Hemodialysis; Heparin

Indexed keywords

HEMOGLOBIN; HEPARIN; TISSUE PLASMINOGEN ACTIVATOR; WARFARIN;

ARTICLE; ARTIFICIAL KIDNEY; BIOCOMPATIBILITY; BLOOD FLOW VELOCITY; CONTROLLED STUDY; DIALYSIS CATHETER; DRUG COST; HEMODIALYSIS; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; RETROSPECTIVE STUDY;

CATHETERIZATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG COSTS; HEPARIN; HUMANS; RENAL DIALYSIS; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33846364964     PISSN: 14927535     EISSN: 15424758     Source Type: Journal    
DOI: 10.1111/j.1542-4758.2007.00159.x     Document Type: Article

References (5)

1. Weijmer MC, van den Dorpel MA for the CITRATE Study Group et al. Randomized, clinical trial comparison of trisodium citrate 30% and heparin as catheter-locking solution in hemodialysis patients. J Am Soc Nephrol. 2005; 16: 2769-2777.
2. Stas KJ, Vanwalleghem J, Moor BD, Keuleers H. Trisodium citrate 30% vs heparin 5% as catheter lock in the interdialytic period in twin-or double-lumen dialysis catheters for intermittent hemodialysis. Nephrol Dial Transplant. 2001; 16: 1521-1522.
3. NKF-K/DOQI clinical practice guidelines for vascular access: Update 2000. Am J Kidney Dis. 2001; 37: S137-S181.
4. Buturovi J, Ponikar R, Kandus A, Boh M, Klinkmann J, Ivanovich P. Filling hemodialysis catheters in the interdialytic period: Heparin versus citrate versus polygeline: A prospective randomized study. Artif Organs. 1998; 22: 945-947.
5. OShea SI, Ortel T, Kovalik EC. Alternative methods of anticoagulation for dialysis-dependent patients with heparin-induced thrombocytopenia. Sem Dial. 2003; 16: 61-67.